At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added...
EMA’s safety committee (PRAC) has concluded today (7 April) that unusual blood clots with low blood platelets should be listed as very rare side effects of...
EMA has received an application for conditional marketing authorization (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as...
EMA has recommended granting a conditional marketing authorization for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of...
Over the last few weeks, EMA has made good progress on the assessment of the marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine. A continuous dialogue...
EMA’s human medicines committee (CHMP) and its experts have been working intensively over the past weeks to evaluate data submitted by BioNTech and Pfizer in the...
EU leaders met via video conference this evening (19 December) to discuss the EU response to the COVID-19 pandemic. European Commission President Ursula von der Leyen...